Intranasal concentration gradient of yupingfeng promotes induction of microRNA-21 by PTEN to reverse activation of OVA mimicking allergic rhinitis

Huang, Xiaopeng; Liu, B.

doi:10.1016/j.reval.2019.03.007

Cited by 7 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous research [21], symptom scores returned to normal on the 14th day of MYN administration in animal models. e short-term treatment course of nasal corticosteroids for AR is 2-12 weeks [37].…”

Section: Discussionsupporting

confidence: 55%

“…All of the herbs in MYN are herbs with high safety. Moreover, MYN has been used in the clinic for more than 20 years, and the efficacy and safety of MYN have been approved [18][19][20][21][22][23].…”

Section: Discussionmentioning

confidence: 99%

“…erefore, the modified YPF has been made into a nasal spray named the modified Yupingfeng nasal spray (MYN), which has the function of "replenishing lung Qi to consolidate exterior and activating blood to open the orifice." In more than two decades of clinical and animal research, previous studies have shown that MYN can effectively improve the symptoms of AR patients and animal models, reduce the expression of inflammatory factors, regulate immune homeostasis, improve blood stasis, and repair the epithelial barrier of the nasal mucosa [18][19][20][21][22][23]. Most importantly, we observed that the 4-week follow-up recurrence rate was lower in the MYN group than in the mometasone furoate aqueous nasal spray group [23].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Modified Yupingfeng Nasal Spray in Controlling the Recurrence of Persistent and Moderate-Severe Allergic Rhinitis: Study Protocol for a Multicenter, Open-Label, Randomized, and Parallel-Arm Trial

Liu

Wang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Recurrent episode of allergic rhinitis (AR) is one of the leading illnesses that affects patients. However, there is little research evidence to support pharmacotherapy for AR recurrence. Therefore, this study was designed to explore the efficacy of pharmacotherapy in the control of the recurrence of AR. Methods. In this study, a multicenter, open-label, randomized, and parallel-arm trial will be conducted at three study centers. A total of 190 subjects aged 18–65 with persistent and moderate-severe AR (Qi deficiency and blood stasis syndrome) will be randomly assigned to receive the modified Yupingfeng nasal spray or mometasone furoate aqueous nasal spray. When subjects’ rhinitis control assessment test (RCAT) score is >21 for two weeks, they will stop taking the medication and enter the follow-up. Once a relapse occurs, the time point will be recorded, and the follow-up stops. The primary outcome is the six-month recurrence rate of AR after intervention withdrawal. The secondary outcomes are the one-month recurrence rate of AR, the RCAT score, the duration of follow-up, the duration of medication, the nasal endoscopic results, and questionnaires to evaluate symptoms, signs, and quality of life. The mechanism outcomes include some indicators that may be associated with AR recurrence. In addition, electrocardiograms and other safety indicators will be applied to evaluate the drug’s safety. Discussion. This is the first study to explore the efficacy of traditional Chinese medicine nasal spray on AR from the perspective of controlling recurrence. The results of this trial may provide valuable clinical evidence for controlling the recurrence of this disease by pharmacotherapy. Trial Registration. This study was registered with registration number ChiCTR2100047053 (Chinese Clinical Trial Registry, https://www.chictr.org.cn/showproj.aspx?proj=127432 on June 7, 2021).

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 99%